Omacetaxine mepesuccinate for the treatment of leukemia

Bibliography

• Dohner H, Estey EH, Amadori S, Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-74
   PubMed Web of Science ®Google Scholar
• Ofran Y, Rowe JM. Induction and postremission strategies in acute myeloid leukemia: what is new? Curr Opin Hematol 2011;18:83-8
   PubMed Web of Science ®Google Scholar
• Schiffer CA. “I am older, not elderly,” said the patient with acute myeloid leukemia. J Clin Oncol 2010;28:521-3
   PubMed Web of Science ®Google Scholar
• Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640-53
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-51
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet 2007;370:342-50
   PubMed Web of Science ®Google Scholar
• Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018-29
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res 2008;14:4392-9
   PubMed Web of Science ®Google Scholar
• Efferth T, Li PC, Konkimalla VS, From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 2007;13:353-61
   PubMed Web of Science ®Google Scholar
• Powell RG, Weisleder D, Smith CR Jr, Structures of harringtonine, isoharringtonine, and homoharringtonine. Tetrahedron Lett 1970;11:815-18
   Google Scholar
• Powell RG, Weisleder D, Smith CR Jr. Antitumor alkaloids for Cephalataxus harringtonia: structure and activity. J Pharm Sci 1972;61:1227-30
   PubMed Web of Science ®Google Scholar
• Grem JL, Cheson BD, King SA, Cephalotaxine esters: antileukemic advance or therapeutic failure? J Natl Cancer Inst 1988;80:1095-103
   PubMed Web of Science ®Google Scholar
• Robin J-P, Dhal R, Dujardin G, The first semi-synthesis of enantiopure homoharringtonine via anhydrohomoharringtonine from a preformed chiral acyl moiety. Tetrahedron Lett 1999;40:2931-4
   Web of Science ®Google Scholar
• Huang MT. Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol Pharmacol 1975;11:511-19
   PubMedGoogle Scholar
• Fresno M, Jimenez A, Vazquez D. Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem 1977;72:323-30
   PubMedGoogle Scholar
• Gurel G, Blaha G, Moore PB, U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J Mol Biol 2009;389:146-56
   PubMed Web of Science ®Google Scholar
• Baaske DM, Heinstein P. Cytotoxicity and cell cycle specificity of homoharringtonine. Antimicrob Agents Chemother 1977;12:298-300
   PubMed Web of Science ®Google Scholar
• Chou TC, Schmid FA, Feinberg A, Uptake, initial effects, and chemotherapeutic efficacy of harringtonine in murine leukemic cells sensitive and resistant to vincristine and other chemotherapeutic agents. Cancer Res 1983;43:3074-9
   PubMed Web of Science ®Google Scholar
• Visani G, Russo D, Ottaviani E, Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Leukemia 1997;11:624-8
   PubMed Web of Science ®Google Scholar
• Tang R, Faussat AM, Majdak P, Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther 2006;5:723-31
   PubMed Web of Science ®Google Scholar
• Allan EK, Holyoake TL, Craig AR, Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia 2011;25(6):985-94
   Web of Science ®Google Scholar
• Chen Y, Hu Y, Michaels S, Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 2009;23:1446-54
   PubMed Web of Science ®Google Scholar
• Kuroda J, Kamitsuji Y, Kimura S, Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin. Int J Hematol 2008;87:507-15
   PubMed Web of Science ®Google Scholar
• Chen R, Guo L, Chen Y, Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood 2011;117:156-64
   PubMed Web of Science ®Google Scholar
• Robert F, Carrier M, Rawe S, Altering chemosensitivity by modulating translation elongation. PLoS One 2009;4:e5428
   PubMed Web of Science ®Google Scholar
• Zhou JY, Chen DL, Shen ZS, Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro. Cancer Res 1990;50:2031-5
   PubMed Web of Science ®Google Scholar
• Tong H, Ren Y, Zhang F, Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells. Eur J Haematol 2008;81:259-66
   PubMed Web of Science ®Google Scholar
• Cobb WR, Bogden AE, Reich SD, Activity of two phase I drugs, homoharringtonine and tricyclic nucleotide, against surgical explants of human tumors in the 6-day subrenal capsule assay. Cancer Treat Rep 1983;67:173-8
   PubMedGoogle Scholar
• Takemura Y, Ohnuma T, Chou TC, Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells. Cancer Chemother Pharmacol 1985;14:206-10
   PubMed Web of Science ®Google Scholar
• Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 2006;66:10959-66
   PubMed Web of Science ®Google Scholar
• Kano Y, Akutsu M, Tsunoda S, In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001;97:1999-2007
   PubMed Web of Science ®Google Scholar
• Scappini B, Onida F, Kantarjian HM, In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer 2002;94:2653-62
   PubMed Web of Science ®Google Scholar
• Tipping AJ, Mahon FX, Zafirides G, Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 2002;16:2349-57
   PubMed Web of Science ®Google Scholar
• Savaraj N, Lu K, Dimery I, Clinical pharmacology of homoharringtonine. Cancer Treat Rep 1986;70:1403-7
   PubMedGoogle Scholar
• Ni D, Ho DH, Vijjeswarapu M, Metabolism of homoharringtonine, a cytotoxic component of the evergreen plant Cephalotaxus harringtonia. J Exp Ther Oncol 2003;3:47-52
   PubMedGoogle Scholar
• Savaraj N, Feun LG, Lu K, Central nervous system (CNS) penetration of homoharringtonine (HHT). J Neurooncol 1987;5:77-81
   PubMed Web of Science ®Google Scholar
• Levy V, Zohar S, Bardin C, A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. Br J Cancer 2006;95:253-9
   PubMed Web of Science ®Google Scholar
• Institute of Materia Medica CAoMS. The antitumor effects and pharmacologic actions of harringtonine. Chin Med J (Engl) 1977;3:131-6
   PubMed Web of Science ®Google Scholar
• Jiang TL, Liu RH, Salmon SE. Comparative in vitro antitumor activity of homoharringtonine and harringtonine against clonogenic human tumor cells. Invest New Drugs 1983;1:21-5
   PubMedGoogle Scholar
• O'Dwyer PJ, King SA, Hoth DF, Homoharringtonine–perspectives on an active new natural product. J Clin Oncol 1986;4:1563-8
   PubMed Web of Science ®Google Scholar
• Marin D, Kaeda JS, Andreasson C, Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 2005;103:1850-5
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Garcia-Manero G, Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007;109:248-55
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Talpaz M, Santini V, Homoharringtonine: history, current research, and future direction. Cancer 2001;92:1591-605
   PubMed Web of Science ®Google Scholar
• Feldman E, Arlin Z, Ahmed T, Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Leukemia 1992;6:1189-91
   PubMed Web of Science ®Google Scholar
• Ye JS, Wang XH, Feng GH, Small-dose Harringtonine induces complete remission in patients with acute promyelocytic leukemia. Leukemia 1988;2:427-9
   PubMed Web of Science ®Google Scholar
• Hou CH, Zhang ZY. Intrathecal injection of harringtonine and homoharringtonine in treating central nervous system leukemia–clinical analysis of 26 cases (author's transl). Zhonghua Yi Xue Za Zhi 1981;61:530-2
   PubMedGoogle Scholar
• Gu LF, Zhang WG, Wang FX, Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia. J Cancer Res Clin Oncol 2011;137(6):997-1003
   Web of Science ®Google Scholar
• Huang BT, Zeng QC, Yu J, High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and postinduction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China. Med Oncol 2011 Jan 22. [Epub ahead of print]
   Web of Science ®Google Scholar
• Jin J, Jiang DZ, Mai WY, Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia 2006;20:1361-7
   PubMed Web of Science ®Google Scholar
• Mi Y, Xue Y, Yu W, Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype. Leuk Lymphoma 2008;49:524-30
   PubMed Web of Science ®Google Scholar
• Wang J, Lu S, Yang J, A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China. J Hematol Oncol 2009;2:32
   PubMed Web of Science ®Google Scholar
• Wu L, Li X, Su J, Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome. Leuk Lymphoma 2009;50:1461-7
   PubMed Web of Science ®Google Scholar
• Zhang ZY, Hou CH, Zhu YF. A preliminary therapeutic analysis of 82 cases of chronic granulocytic leukemia treated with harringtonine. Zhonghua Nei Ke Za Zhi 1986;25:156-7. 90
   PubMedGoogle Scholar
• O'Brien S, Kantarjian H, Keating M, Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995;86:3322-6
   PubMed Web of Science ®Google Scholar
• O'Brien S, Kantarjian H, Koller C, Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 1999;93:4149-53
   PubMed Web of Science ®Google Scholar
• Li YF, Deng ZK, Xuan HB, Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy. Chin Med J (Engl) 2009;122:1413-17
   PubMed Web of Science ®Google Scholar
• O'Brien S, Talpaz M, Cortes J, Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 2002;94:2024-32
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Talpaz M, Smith TL, Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol 2000;18:3513-21
   PubMed Web of Science ®Google Scholar
• Stone RM, Donohue KA, Stock W, A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol 2009;63:859-64
   PubMed Web of Science ®Google Scholar
• O'Brien S, Giles F, Talpaz M, Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 2003;98:888-93
   PubMed Web of Science ®Google Scholar
• Ayoubi M, Kantarjian HM, Wierda W, A Phase 2 study of the Combination of omacetaxine and imatinib in the treatment of patients with chronic myeloid leukemia (CML) in advanced stages or after failure to imatinib. Volume 114 ASH Annual Meeting Abstracts; 2009. p. 2193
   Google Scholar
• Fang B, Li N, Song Y, Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib. Ann Hematol 2010;89:1099-105
   PubMed Web of Science ®Google Scholar
• Li YF, Liu X, Liu DS, The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy. Leuk Lymphoma 2009;50:1889-91
   PubMed Web of Science ®Google Scholar
• Cortes-Franco J, Raghunadharao D, Parikh P, Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid Leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors - results of a multicenter phase 2/3 study. Volume 114 ASH Annual Meeting Abstracts; 2009. p. 861
   Google Scholar
• Nicolini FE, Morisset S, Hochhaus A, The presence of the BCR-ABL T315I mutation in chronic phase chronic myelogenous leukemia resistant to tyrosine kinase inhibitors profoundly compromises overall survival and progression free survival. preliminary results of a matched pair analysis. Volume 116 ASH Annual Meeting Abstracts; 2010. p. 3410
   Google Scholar
• de Lavallade H, Khorashad JS, Davis HP, Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood 2007;110:2779-80
   PubMed Web of Science ®Google Scholar
• Legros L, Hayette S, Nicolini FE, BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge? Leukemia 2007;21:2204-6
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Chomel JC, Roy L, The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge. Clin Lymphoma Myeloma Leuk 2010;10:394-9
   PubMed Web of Science ®Google Scholar
• Cortes-Franco J, Khoury HJ, Nicolini FE, Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant Chronic myeloid leukemia (CML) patients who harbor the Bcr- Abl T315I mutation-results of an ongoing multicenter phase 2/3 Study. Volume 114 ASH Annual Meeting Abstracts; 2009. p. 644
   Google Scholar
• ODAC Briefing Book: OMAPROTM (omacetaxine mepesuccinate). 2010 [cited; 1-71]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM204345.pdf
   Google Scholar
• Berman E. Omacetaxine: the FDA decision. Clin Adv Hematol Oncol 2011;9:57-8
   PubMedGoogle Scholar
• Nanda N, Cortes C, Lipton J, Treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients who harbor the BCR-ABL T315I mutation with subcutaneous omacetaxine results in improved survival compared to historical data. Haematologica 2011;96(s2):1012
   Google Scholar
• Wilkoff LJ, Dulmadge DA, Laster WR Jr, Effect of homoharringtonine on the viability of murine leukemia P388 cells resistant to either adriamycin, vincristine, or 1-beta-D-arabinofuranosylcytosine. Cancer Chemother Pharmacol 1989;23:145-50
   PubMed Web of Science ®Google Scholar
• Russo D, Michelutti A, Melli C, MDR-related P170-glycoprotein modulates cytotoxic activity of homoharringtonine. Leukemia 1995;9:513-16
   PubMed Web of Science ®Google Scholar
• Tebbi CK, Chervinsky D, Baker RM. Modulation of drug resistance in homoharringtonine-resistant C-1300 neuroblastoma cells with cyclosporine A and dipyridamole. J Cell Physiol 1991;148:464-71
   PubMed Web of Science ®Google Scholar
• Zhou DC, Ramond S, Viguie F, Sequential emergence of MRP- and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines. Int J Cancer 1996;65:365-71
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Keating MJ, Walters RS, Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer 1989;63:813-17
   PubMed Web of Science ®Google Scholar
• Sylvester RK, Lobell M, Ogden W, Homoharringtonine-induced hyperglycemia. J Clin Oncol 1989;7:392-5
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O'Brien SG, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9
   PubMed Web of Science ®Google Scholar
• Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 2009;114:5426-35
   PubMed Web of Science ®Google Scholar
• Mahadeo KM, Cole PD. Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 [corrected] 35INS. Blood 2010;115:3852
   PubMed Web of Science ®Google Scholar
• Mahon FX, Rea D, Guilhot J, Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-35
   PubMed Web of Science ®Google Scholar
• Bhatia R, Holtz M, Niu N, Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003;101:4701-7
   PubMed Web of Science ®Google Scholar
• Graham SM, Jorgensen HG, Allan E, Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-25
   PubMed Web of Science ®Google Scholar
• Holtz MS, Slovak ML, Zhang F, Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002;99:3792-800
   PubMed Web of Science ®Google Scholar
• Xu WL, Jin J, Qian WB. Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes. Chin Med J (Engl) 2010;123:108-10
   PubMed Web of Science ®Google Scholar
• Eckelbarger JD, Wilmot JT, Epperson MT, Synthesis of antiproliferative Cephalotaxus esters and their evaluation against several human hematopoietic and solid tumor cell lines: uncovering differential susceptibilities to multidrug resistance. Chemistry (Easton) 2008;14:4293-306
   PubMed Web of Science ®Google Scholar